Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
NCX 470, a Nitric Oxide Donating Bimatoprost versus Latanoprost Has Greater Proportion of Subjects Achieving ≥10 mmHg IOP Decrease in Phase 3 Trial

July 3, 2023

View Press Release Corporate presentation Contact us
Previous